4th Quarter

4th Quarter

HEMERA WINS MARCHI+

Hemera has been awarded the Marchi+ call, the incentive aimed at economically valorizing the registration of European Union and international trademarks, promoted by the Ministry of Enterprises and Made in Italy through the Invitalia Agency. This recognition represents an important step forward in enhancing the value of our intellectual property, particularly the REMaST trademark registered in Europe and in 12 non-European countries.

 

ADVANCES IN THE OBSERVATIONAL CLINICAL STUDY

Recruitment and monitoring activities for patients with complete spinal cord injury continue at the Niguarda Hospital in Milan, Bergamo Hospital, Villa Beretta in Lecco, and the Humanitas Clinical Institute. To date, 6 patients with complete sensorimotor spinal cord injury (ASIA A) have been recruited and are being monitored for twelve months after the trauma, with the collection of electrophysiological, sensory, and motor data, in preparation for the upcoming clinical study in which REMaST®  therapy will be administered to humans for the first time.

PROGRESS IN TECHNOLOGY TRANSFER FOR THE PRODUCTION OF REMaST

Hemera has made significant progress in the technology transfer for the production of the REMaST® product for clinical use. In collaboration with the selected Cell Factory, the necessary activities have been initiated to ensure a high-quality production process, in accordance with the standards required by regulatory agencies. Standard tests have been finalized to certify the efficacy of ReMAST® intended for human use, and the validation of quality controls generated using GMP (Good Manufacturing Practices) products authorized for clinical use in humans has been completed.